HRP20050119A2 - Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals - Google Patents

Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals

Info

Publication number
HRP20050119A2
HRP20050119A2 HR20050119A HRP20050119A HRP20050119A2 HR P20050119 A2 HRP20050119 A2 HR P20050119A2 HR 20050119 A HR20050119 A HR 20050119A HR P20050119 A HRP20050119 A HR P20050119A HR P20050119 A2 HRP20050119 A2 HR P20050119A2
Authority
HR
Croatia
Prior art keywords
formula
acylated
heteroaryl
compounds
enzyme
Prior art date
Application number
HR20050119A
Other languages
English (en)
Croatian (hr)
Inventor
Strobel Hartmut
Wohlfart Paulus
Original Assignee
Sanofi-Aventis Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis Deutschland Gmbh filed Critical Sanofi-Aventis Deutschland Gmbh
Publication of HRP20050119A2 publication Critical patent/HRP20050119A2/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04Ortho- or peri-condensed ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
HR20050119A 2002-08-07 2005-02-04 Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals HRP20050119A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02017586A EP1388342A1 (en) 2002-08-07 2002-08-07 Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
PCT/EP2003/008103 WO2004014372A1 (en) 2002-08-07 2003-07-24 Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
HRP20050119A2 true HRP20050119A2 (en) 2006-05-31

Family

ID=30129194

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050119A HRP20050119A2 (en) 2002-08-07 2005-02-04 Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals

Country Status (27)

Country Link
EP (2) EP1388342A1 (pl)
JP (1) JP4608315B2 (pl)
KR (1) KR101061727B1 (pl)
CN (1) CN100337626C (pl)
AR (1) AR040790A1 (pl)
AT (1) ATE524178T1 (pl)
AU (1) AU2003251466B2 (pl)
BR (1) BR0313240A (pl)
CA (1) CA2494302C (pl)
DK (1) DK1534277T3 (pl)
ES (1) ES2373651T3 (pl)
HK (1) HK1079427A1 (pl)
HR (1) HRP20050119A2 (pl)
IL (1) IL166494A (pl)
MA (1) MA27331A1 (pl)
ME (1) MEP25808A (pl)
MX (1) MXPA05000833A (pl)
MY (1) MY140840A (pl)
NO (1) NO330011B1 (pl)
NZ (1) NZ538090A (pl)
PL (1) PL212119B1 (pl)
PT (1) PT1534277E (pl)
RS (1) RS52385B (pl)
RU (1) RU2338743C2 (pl)
TW (1) TWI328582B (pl)
WO (1) WO2004014372A1 (pl)
ZA (1) ZA200410274B (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004042607A1 (de) 2004-09-03 2006-03-09 Bayer Healthcare Ag Substituierte Phenylaminothiazole und ihre Verwendung
EP1741708A1 (en) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals
EP1741709A1 (en) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
DE102006042143A1 (de) 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Neue substituierte Bipyridin-Derivate und ihre Verwendung
EP1905764A1 (en) * 2006-09-30 2008-04-02 Sanofi-Aventis Substituted 2-Phenyl-benzimidazoles and their use as pharmaceuticals
EP1923062A1 (en) 2006-11-16 2008-05-21 sanofi-aventis Imidazo[2,1-b]thiazoles and their use as pharmaceuticals
DE102006056740A1 (de) 2006-12-01 2008-06-05 Bayer Healthcare Ag Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung
DE102006056739A1 (de) 2006-12-01 2008-06-05 Bayer Healthcare Ag Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung
EP1939180A1 (en) 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
EP1939181A1 (en) 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
EP1964841A1 (en) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]azine and their use as pharmaceuticals
EP1964840A1 (en) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]pyridines and their use as pharmaceuticals
DE102007035367A1 (de) 2007-07-27 2009-01-29 Bayer Healthcare Ag Substituierte Aryloxazole und ihre Verwendung
DE102007036076A1 (de) 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
DE102007061764A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag Anellierte Cyanopyridine und ihre Verwendung
DE102007061763A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituierte azabicyclische Verbindungen und ihre Verwendung
DE102008013587A1 (de) 2008-03-11 2009-09-17 Bayer Schering Pharma Aktiengesellschaft Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung
WO2009143992A1 (de) 2008-05-29 2009-12-03 Bayer Schering Pharma Aktiengesellschaft 2-alkoxy-substituierte dicyanopyridine und ihre verwendung
US8822449B2 (en) * 2008-09-02 2014-09-02 Sanofi Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof
DE102008062567A1 (de) 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Dipeptoid-Prodrugs und ihre Verwendung
CN101759683B (zh) * 2008-12-25 2011-12-28 哈尔滨誉衡药业股份有限公司 二氢化茚酰胺化合物制备方法、包含其的药物组合物、及其作为蛋白激酶抑制剂的应用
DE102009006602A1 (de) 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
DE102010030688A1 (de) 2010-06-30 2012-01-05 Bayer Schering Pharma Aktiengesellschaft Substituierte Dicyanopyridine und ihre Verwendung
US20120058983A1 (en) 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
RU2545758C1 (ru) * 2014-03-20 2015-04-10 Общество с ограниченной ответственностью "Алион" Бициклические пиримидины или их фармацевтически приемлемые соли-активаторы антиоксидантной программы и их применение в качестве цитопротекторов
ES2896400T3 (es) 2014-08-01 2022-02-24 Nuevolution As Compuestos activos frente a bromdominios
GB201601301D0 (en) * 2016-01-25 2016-03-09 Takeda Pharmaceutical Novel compounds
RU2764243C2 (ru) 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Гетероциклические соединения в качестве ингибиторов PAD
PT3697785T (pt) 2017-10-18 2023-04-03 Jubilant Epipad LLC Compostos de imidazopiridina como inibidores de pad
KR20200085836A (ko) 2017-11-06 2020-07-15 주빌런트 프로델 엘엘씨 Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체
PT3704120T (pt) 2017-11-24 2024-07-03 Jubilant Episcribe Llc Compostos heterocíclicos como inibidores de prmt5
BR112020018610A2 (pt) 2018-03-13 2020-12-29 Jubilant Prodel LLC Compostos de fórmula i, fórmula ii, fórmula iii, fórmula iv, fórmula v, fórmula vi, ou seus polimorfos, estereoisômeros, tautômeros, profármacos, solvatos e sais farmaceuticamente aceitáveis dos mesmos e uso dos mesmos; processo de preparação; composição farmacêutica; e método para o tratamento e/ou prevenção de várias doenças, que incluem câncer e doenças infecciosas

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08325234A (ja) * 1995-05-30 1996-12-10 Yamanouchi Pharmaceut Co Ltd 安息香酸誘導体又はその塩
WO1999048492A1 (fr) * 1998-03-26 1999-09-30 Japan Tobacco Inc. Derives d'amide et antagonistes de nociceptine
JP3013989B2 (ja) * 1998-03-26 2000-02-28 日本たばこ産業株式会社 アミド誘導体及びノシセプチンアンタゴニスト
WO2001068652A1 (en) * 2000-03-17 2001-09-20 Novo Nordisk A/S Condensed imidazoles as histamine h3 receptor ligands
PE20020856A1 (es) * 2001-02-13 2002-11-11 Aventis Pharma Gmbh 1,2,3,4-tetrahidronaftil aminas aciladas
TWI243164B (en) * 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
PE20020870A1 (es) * 2001-02-13 2002-11-18 Aventis Pharma Gmbh 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas
TWI241190B (en) * 2001-02-13 2005-10-11 Aventis Pharma Gmbh 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical

Also Published As

Publication number Publication date
CA2494302C (en) 2011-11-29
CN100337626C (zh) 2007-09-19
DK1534277T3 (da) 2012-01-09
AU2003251466B2 (en) 2009-04-23
WO2004014372A1 (en) 2004-02-19
AR040790A1 (es) 2005-04-20
MXPA05000833A (es) 2005-04-19
MEP25808A (en) 2010-06-10
MY140840A (en) 2010-01-29
EP1534277A1 (en) 2005-06-01
ES2373651T3 (es) 2012-02-07
HK1079427A1 (en) 2006-04-07
JP4608315B2 (ja) 2011-01-12
KR20050059056A (ko) 2005-06-17
RU2005106292A (ru) 2005-09-10
IL166494A (en) 2011-12-29
TWI328582B (en) 2010-08-11
RU2338743C2 (ru) 2008-11-20
TW200412949A (en) 2004-08-01
RS52385B (en) 2013-02-28
IL166494A0 (en) 2006-01-15
PL373279A1 (pl) 2005-08-22
MA27331A1 (fr) 2005-05-02
PT1534277E (pt) 2011-12-06
ATE524178T1 (de) 2011-09-15
AU2003251466A1 (en) 2004-02-25
EP1534277B1 (en) 2011-09-14
CA2494302A1 (en) 2004-02-19
NO330011B1 (no) 2011-02-07
ZA200410274B (en) 2006-07-26
CN1674895A (zh) 2005-09-28
NZ538090A (en) 2007-02-23
NO20050830L (no) 2005-02-16
PL212119B1 (pl) 2012-08-31
KR101061727B1 (ko) 2011-09-05
JP2005538124A (ja) 2005-12-15
BR0313240A (pt) 2005-09-27
EP1388342A1 (en) 2004-02-11
RS20050097A (en) 2007-06-04

Similar Documents

Publication Publication Date Title
HRP20050119A2 (en) Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
MEP60508A (en) Acylated arylcycloalkylamines and their use as pharmaceuticals
IL166493A0 (en) Acylamino-substituted heteroaromatic compounds andtheir use as pharmaceuticals
MEP43008A (en) Indole-2-carboxamides as factor xa inhibitors
NO20032820D0 (no) Oksybenzamidderivater som faktor XA inhibitorer
RS70104A (en) Nicotinamide derivatives useful as pde4 inhibitors
HUP0401538A2 (hu) Új, helyettesített aminometilcsoportot tartalmazó N-(arilszulfonil)-béta-aminosav-származékok, előállításukra alkalmas eljárás és a vegyületeket tartalmazó gyógyászati készítmények
MX2008000019A (es) Amidas sustituidas con heteroarilo que comprenden un grupo enlazador insaturado o ciclico, y su uso como productos farmaceuticos.
CA2340405A1 (en) Substituted 4-amino-2-aryl-pyrimidines, their production and use and pharmaceutical preparations containing same
DE602004020761D1 (de) INDAZOLDERIVATE ALS FAKTOR Xa-INHIBITOREN
NO20052520L (no) Nye sulfamider
NO20025810D0 (no) Faktor VIIA-inhibitoriske (tio)ureaderivater, deres fremstilling og anvendelse
MXPA05011267A (es) Derivados de la triaza-y tetraaza-antracenodiona, su preparacion y su uso como productos farmaceuticos.
MEP54708A (en) N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
BR9911942B1 (pt) "n-arilamidas de ácido sulfonilaminocarboxílico como ativadores da ciclasse de guanilato e composições farmacêuticas contendo as mesmas"
YU86101A (sh) Inhibitori faktora viia
DE60006936D1 (de) Substituierte 4-amino-2-aryltetrahydrochinazoline, deren herstellung, deren verwendung und diese enthaltende pharmazeutische zusammenstellungen
NO995594D0 (no) Nye substituerte heterocykliske forbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem
DE602004013577D1 (de) TRIAZOLDERIVATE ALS FAKTOR-Xa-INHIBITOREN
MX2008000044A (es) Amidas sustituidas con heteroarilo que comprenden un grupo enlazador saturado, y su uso como agentes farmaceuticos.
ATE179424T1 (de) N-heteroaryl substituierte propanamid-derivate brauchbar zur behandlung cardiovascularer krankheiten
TW200716620A (en) Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide-derivatives as factor Xa inhibitors
IL139317A0 (en) Benzimdazole and benzoxazole derivatives and pharmaceutical compositions contining the same
UA48064A1 (uk) Етиловий ефір 2-сульфамоїлмалонанілової кислоти, який проявляє протизапальну активність

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20120606

Year of fee payment: 10

OBST Application withdrawn